NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · GENE · USD
Stock price, earnings
Quote as of Nov 14, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genetic Technologies Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer. This innovative test is promoted to various medical specialists, including professionals in breast healthcare and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment experts like breast surgeons. Beyond BREVAGenplus, the company's portfolio includes other cancer risk assessment tests marketed under the 'GeneType' brand, notably 'GeneType for Colorectal Cancer' and 'GeneType for Breast Cancer'. Furthermore, Genetic Technologies is actively developing additional risk assessment tools for a diverse range of conditions, such as cardiovascular diseases, type 2 diabetes, prostate cancer, and melanoma. Its services extend to general genetic testing, encompassing applications in medical, animal, forensic, and plant diagnostics. Genetic Technologies maintains active research and collaboration agreements with several prestigious institutions, including the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, The Ohio State University, and Shivom. The company was established in 1987 and operates from its headquarters in Fitzroy, Australia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$4.03+$0.01 (+0.12%)
Genetron Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
$2.35-$0.01 (-0.21%)
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$3.02-$0.07 (-2.27%)
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$3.87+$0.14 (+3.75%)
iCAD, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$2.09-$0.01 (-0.48%)
HilleVax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.69% below the high.
